Telix Pharmaceuticals (ASX:TLX) completed its acquisition of US radiopharmacy network RLS for an upfront cash payment of $230 million and a deferred payment of $20 million, according to a Tuesday filing with the Australian bourse.
RLS will continue to operate as a standalone business within Telix Manufacturing Solutions, per the filing. The deal is part of the biopharmaceutical company's strategy to create an integrated radiopharmaceutical ecosystem.